PortfoliosLab logoPortfoliosLab logo
GILD vs. BIIB
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

GILD vs. BIIB - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Gilead Sciences, Inc. (GILD) and Biogen Inc. (BIIB). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, GILD achieves a 5.84% return, which is significantly lower than BIIB's 11.63% return. Over the past 10 years, GILD has outperformed BIIB with an annualized return of 7.70%, while BIIB has yielded a comparatively lower -3.81% annualized return.


GILD

1D
0.15%
1M
-3.22%
YTD
5.84%
6M
6.65%
1Y
21.64%
3Y*
22.54%
5Y*
18.21%
10Y*
7.70%

BIIB

1D
0.25%
1M
3.87%
YTD
11.63%
6M
7.95%
1Y
48.98%
3Y*
-13.37%
5Y*
-7.25%
10Y*
-3.81%
*Multi-year figures are annualized to reflect compound growth (CAGR)

GILD vs. BIIB - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
GILD
Gilead Sciences, Inc.
5.84%36.59%18.68%-1.99%23.63%29.95%-6.70%7.88%-9.92%2.96%
BIIB
Biogen Inc.
11.63%15.09%-40.91%-6.55%15.42%-2.02%-17.48%-1.39%-5.54%12.34%

Correlation

The correlation between GILD and BIIB is 0.29, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.29

Correlation (3Y)
Calculated over the trailing 3-year period

0.36

Correlation (5Y)
Calculated over the trailing 5-year period

0.39

Correlation (10Y)
Calculated over the trailing 10-year period

0.44

Correlation (All Time)
Calculated using the full available price history since Jan 23, 1992

0.38

The correlation between GILD and BIIB shifts across timeframes, from 0.29 (1 year) to 0.44 (10 years), reflecting how their relationship changes across market environments.

Fundamentals

EPS

GILD:

$7.35

BIIB:

$12.48

PE Ratio

GILD:

17.58

BIIB:

15.74

PEG Ratio

GILD:

0.04

BIIB:

1.09

PS Ratio

GILD:

5.45

BIIB:

2.19

Total Revenue (TTM)

GILD:

$29.74B

BIIB:

$9.86B

Gross Profit (TTM)

GILD:

$18.74B

BIIB:

$5.06B

EBITDA (TTM)

GILD:

$12.88B

BIIB:

$2.24B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

GILD vs. BIIB — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

GILD
GILD Risk / Return Rank: 6565
Overall Rank
GILD Sharpe Ratio Rank: 6868
Sharpe Ratio Rank
GILD Sortino Ratio Rank: 6363
Sortino Ratio Rank
GILD Omega Ratio Rank: 5959
Omega Ratio Rank
GILD Calmar Ratio Rank: 6666
Calmar Ratio Rank
GILD Martin Ratio Rank: 6767
Martin Ratio Rank

BIIB
BIIB Risk / Return Rank: 8181
Overall Rank
BIIB Sharpe Ratio Rank: 8181
Sharpe Ratio Rank
BIIB Sortino Ratio Rank: 7979
Sortino Ratio Rank
BIIB Omega Ratio Rank: 7575
Omega Ratio Rank
BIIB Calmar Ratio Rank: 8585
Calmar Ratio Rank
BIIB Martin Ratio Rank: 8585
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

GILD vs. BIIB - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Gilead Sciences, Inc. (GILD) and Biogen Inc. (BIIB). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


GILDBIIBDifference
Sharpe ratioReturn per unit of total volatility

-0.66

Sortino ratioReturn per unit of downside risk

-0.87

Omega ratioGain probability vs. loss probability

1.16

1.26

-0.10

Calmar ratioReturn relative to maximum drawdown

1.23

3.43

-2.20

Martin ratioReturn relative to average drawdown

3.07

8.40

-5.33

GILD vs. BIIB - Sharpe Ratio Comparison

The current GILD Sharpe Ratio is 0.83, which is lower than the BIIB Sharpe Ratio of 1.48. The chart below compares the historical Sharpe Ratios of GILD and BIIB, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


GILDBIIBDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

0.83

1.48

-0.66

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.76

-0.19

+0.95

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.30

-0.09

+0.40

Sharpe Ratio (All Time)

Calculated using the full available price history

0.39

0.23

+0.16

Drawdowns

GILD vs. BIIB - Drawdown Comparison

The maximum GILD drawdown since its inception was -70.83%, smaller than the maximum BIIB drawdown of -89.98%. Use the drawdown chart below to compare losses from any high point for GILD and BIIB.


Loading charts...

Drawdown Indicators


GILDBIIBDifference

Max Drawdown

Largest peak-to-trough decline

-70.83%

-89.98%

+19.15%

Max Drawdown (1Y)

Largest decline over 1 year

-17.65%

-14.34%

-3.31%

Max Drawdown (3Y)

Largest decline over 3 years

-26.59%

-63.82%

+37.23%

Max Drawdown (5Y)

Largest decline over 5 years

-26.59%

-72.66%

+46.07%

Max Drawdown (10Y)

Largest decline over 10 years

-30.47%

-72.66%

+42.19%

Current Drawdown

Current decline from peak

-16.62%

-58.73%

+42.11%

Average Drawdown

Average peak-to-trough decline

-22.16%

-36.61%

+14.45%

Ulcer Index

Depth and duration of drawdowns from previous peaks

7.06%

5.85%

+1.21%

Volatility

GILD vs. BIIB - Volatility Comparison

The current volatility for Gilead Sciences, Inc. (GILD) is 7.26%, while Biogen Inc. (BIIB) has a volatility of 9.84%. This indicates that GILD experiences smaller price fluctuations and is considered to be less risky than BIIB based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


GILDBIIBDifference

Volatility (1M)

Calculated over the trailing 1-month period

7.26%

9.84%

-2.58%

Volatility (6M)

Calculated over the trailing 6-month period

18.55%

24.13%

-5.58%

Volatility (1Y)

Calculated over the trailing 1-year period

26.31%

33.21%

-6.90%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

24.03%

38.38%

-14.35%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

25.49%

41.47%

-15.98%

Dividends

GILD vs. BIIB - Dividend Comparison

GILD's dividend yield for the trailing twelve months is around 2.47%, while BIIB has not paid dividends to shareholders.


PositionTTM20252024202320222021202020192018201720162015
BIIB
Biogen Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
GILD
Gilead Sciences, Inc.
2.47%2.57%3.33%3.70%3.40%3.91%4.67%3.88%3.65%2.90%2.57%1.27%

Financials

GILD vs. BIIB - Financials Comparison

This section allows you to compare key financial metrics between Gilead Sciences, Inc. and Biogen Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


2.00B3.00B4.00B5.00B6.00B7.00B8.00B20222023202420252026
6.96B
2.48B
(GILD) Total Revenue
(BIIB) Total Revenue
Values in USD except per share items

GILD vs. BIIB - Profitability Comparison

The chart below illustrates the profitability comparison between Gilead Sciences, Inc. and Biogen Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

0.0%20.0%40.0%60.0%80.0%20222023202420252026
1.1%
0
Portfolio components
GILD - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Gilead Sciences, Inc. reported a gross profit of 79.20M and revenue of 6.96B. Therefore, the gross margin over that period was 1.1%.

BIIB - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Biogen Inc. reported a gross profit of 0.00 and revenue of 2.48B. Therefore, the gross margin over that period was 0.0%.

GILD - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Gilead Sciences, Inc. reported an operating income of 2.59B and revenue of 6.96B, resulting in an operating margin of 37.2%.

BIIB - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Biogen Inc. reported an operating income of 0.00 and revenue of 2.48B, resulting in an operating margin of 0.0%.

GILD - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Gilead Sciences, Inc. reported a net income of 2.02B and revenue of 6.96B, resulting in a net margin of 29.0%.

BIIB - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Biogen Inc. reported a net income of 319.50M and revenue of 2.48B, resulting in a net margin of 12.9%.


Frequently Asked Questions


GILD and BIIB have a correlation of 0.29, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

BIIB has higher volatility (9.84%) compared to GILD (7.26%). In terms of maximum drawdown, GILD dropped -70.83% vs BIIB's -89.98%.

BIIB currently has the higher Sharpe Ratio (1.48 vs 0.83), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for GILD and BIIB

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer